JPS62145029A - インタ−フエロン組成物 - Google Patents

インタ−フエロン組成物

Info

Publication number
JPS62145029A
JPS62145029A JP61295704A JP29570486A JPS62145029A JP S62145029 A JPS62145029 A JP S62145029A JP 61295704 A JP61295704 A JP 61295704A JP 29570486 A JP29570486 A JP 29570486A JP S62145029 A JPS62145029 A JP S62145029A
Authority
JP
Japan
Prior art keywords
interferon
delta
gamma
combination
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP61295704A
Other languages
English (en)
Japanese (ja)
Inventor
ポール・ジェイソン・レイボウィッツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schering-Plough Corp
Original Assignee
Schering-Plough Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering-Plough Corp filed Critical Schering-Plough Corp
Publication of JPS62145029A publication Critical patent/JPS62145029A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP61295704A 1985-12-11 1986-12-11 インタ−フエロン組成物 Pending JPS62145029A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/807,887 US4806347A (en) 1985-12-11 1985-12-11 Interferon combinations
US807887 2004-03-24

Publications (1)

Publication Number Publication Date
JPS62145029A true JPS62145029A (ja) 1987-06-29

Family

ID=25197366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61295704A Pending JPS62145029A (ja) 1985-12-11 1986-12-11 インタ−フエロン組成物

Country Status (7)

Country Link
US (1) US4806347A (enExample)
EP (1) EP0225759B1 (enExample)
JP (1) JPS62145029A (enExample)
AT (1) ATE76579T1 (enExample)
DE (1) DE3685484D1 (enExample)
ES (1) ES2036526T3 (enExample)
GR (1) GR3005362T3 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE74517T1 (de) * 1987-01-20 1992-04-15 Schering Corp Behandlung von einigen leukaemien mit einer zusammensetzung von interferon-gamma und interferon-alpha.
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
AU782402B2 (en) 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CN1564693A (zh) * 2001-10-05 2005-01-12 印特缪恩股份有限公司 治疗肝纤维化和丙型肝炎病毒感染的方法
AU2003225670A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004078206A1 (en) * 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
EP2305696A3 (en) 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998019A (ja) * 1982-10-25 1984-06-06 ジエネンテク，インコ−ポレイテツド インタ−フエロンの相乗効果

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998019A (ja) * 1982-10-25 1984-06-06 ジエネンテク，インコ−ポレイテツド インタ−フエロンの相乗効果

Also Published As

Publication number Publication date
ES2036526T3 (es) 1993-06-01
DE3685484D1 (enExample) 1992-07-02
US4806347A (en) 1989-02-21
ATE76579T1 (de) 1992-06-15
EP0225759A3 (en) 1989-02-08
EP0225759B1 (en) 1992-05-27
EP0225759A2 (en) 1987-06-16
GR3005362T3 (enExample) 1993-05-24

Similar Documents

Publication Publication Date Title
DE69330032T2 (de) Therapeutisches kombinationspräparat enthaltend interferon
Fossä et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study
US7670620B2 (en) Topical composition for the treatment of psoriasis and related skin disorders
DE69430440T2 (de) Zusammensetzungen zur inhibition von retroviraler verbreitung, die 2',3'-dideoxy-inosin und hydroxyharnstoff enthalten
DE69333321T3 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
JP2888259B2 (ja) インターフェロン−αとヒスタミン、セロトニンまたは相当するレセプター活性を有する物質とを含有するナチュラルキラー細胞（ＮＫ細胞）活性化用製剤
HU206988B (en) Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient
EP0225759B1 (en) Interferon compositions
AU700502B2 (en) Zwitterionic compositions and methods as biological response modifiers
Northfelt Treatment of Kaposi’s sarcoma: current guidelines and future perspectives
JPH02264730A (ja) Ａｔｌｌ治療用吸入剤
Fischl Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma
JP3631245B2 (ja) ＤＮＡウイルス感染の治療のための薬物の製造のための膜翅類昆虫（ｈｙｍｅｎｏｐｔｅｒａ）毒の使用
US20050003023A1 (en) Topical composition for the treatment of psoriasis and related skin disorders
Ho et al. Paradoxical effects of interferon on reactivation of oral infection with herpes simplex virus after microvascular decompression for trigeminal neuralgia
WO1997014420A1 (en) Treating fibrosis in skeletal muscle tissue
JPH04275231A (ja) 事故結果として多外傷を有する危険な患者に於て、臓器拒絶の予防及び（又は）処置に、スーパーオキシドジスムターゼを使用する方法
Geber et al. Action of naloxone on the interferon-lowering activity of morphine in the mouse
Milligan et al. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis.
US5264208A (en) Potentiation of tumor necrosis factor (TNF) of interferon B1 (IFN-B1) antiviral activities by an anti-cachexia agent
Silver et al. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon.
JP3167763B2 (ja) 創傷治癒促進剤
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
KR970005325B1 (ko) 에이즈 발병방지, 치료제 및 그 치료용 조성물
IE893828L (en) Treatment of squamous cell carcinoma intralesionally with¹recombinant human alpha interferon